Literature DB >> 22447485

Expression and clinical significance of NEDD9 in lung tissues.

Jing-Xia Chang1, Feng Gao, Guo-Qiang Zhao, Guo-Jun Zhang.   

Abstract

Neural precursor cell expressed, developmentally downregulated 9 (NEDD9) acts as a scaffold protein and belongs to a family of CAS (Crk-associated substrate) that regulates protein complexes controlling invasion and differentiation. Preclinical research for this gene was predominantly reported in melanomas, glioblastoma, and lymphoma. So we investigated the expression and significance of NEDD9 mRNA and protein in lung tissues. Specifically, we immunohistochemically compared NEDD9 expression and localization in 24 formalin-fixed and paraffin-embedded lung adenocarcinoma tissues with that of surrounding nonneoplastic tissue and five microscopically normal lungs. NEDD9 mRNA levels were quantitatively analyzed by fluorescent quantitative reverse transcription-polymerase chain reaction (FQ-PCR) in frozen tissue specimens of all tumors and 24 matched nonneoplastic lung parenchymas, and protein expression in 16 homogenates of matched neoplastic/nonneoplastic specimens was evaluated by Western blotting. The three techniques showed that NEDD9 is weakly expressed in nonneoplastic lung parenchyma and upregulated in lung adenocarcinoma. Moreover, FQ-PCR indicated a statistically significant correlation between NEDD9 upregulation and higher disease stages (I+II versus III+IV, p=0.001; high and middle versus low differentiation, p<0.001). Our results provide evidence that NEDD9 is upregulated in lung adenocarcinoma, and overexpression of NEDD9 protein has been strongly correlated with staging and differentiation grade and tumor size in lung adenocarcinoma, which demonstrated a poor prognosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22447485     DOI: 10.1007/s12032-012-0213-0

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  21 in total

1.  Identification of a set of genes with developmentally down-regulated expression in the mouse brain.

Authors:  S Kumar; Y Tomooka; M Noda
Journal:  Biochem Biophys Res Commun       Date:  1992-06-30       Impact factor: 3.575

2.  LKB1 modulates lung cancer differentiation and metastasis.

Authors:  Hongbin Ji; Matthew R Ramsey; D Neil Hayes; Cheng Fan; Kate McNamara; Piotr Kozlowski; Chad Torrice; Michael C Wu; Takeshi Shimamura; Samanthi A Perera; Mei-Chih Liang; Dongpo Cai; George N Naumov; Lei Bao; Cristina M Contreras; Danan Li; Liang Chen; Janakiraman Krishnamurthy; Jussi Koivunen; Lucian R Chirieac; Robert F Padera; Roderick T Bronson; Neal I Lindeman; David C Christiani; Xihong Lin; Geoffrey I Shapiro; Pasi A Jänne; Bruce E Johnson; Matthew Meyerson; David J Kwiatkowski; Diego H Castrillon; Nabeel Bardeesy; Norman E Sharpless; Kwok-Kin Wong
Journal:  Nature       Date:  2007-08-05       Impact factor: 49.962

3.  The focal adhesion scaffolding protein HEF1 regulates activation of the Aurora-A and Nek2 kinases at the centrosome.

Authors:  Elena N Pugacheva; Erica A Golemis
Journal:  Nat Cell Biol       Date:  2005-09-25       Impact factor: 28.824

4.  Requirements for localization of p130cas to focal adhesions.

Authors:  T Nakamoto; R Sakai; H Honda; S Ogawa; H Ueno; T Suzuki; S Aizawa; Y Yazaki; H Hirai
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

5.  Focal adhesion kinase regulates beta1 integrin-dependent T cell migration through an HEF1 effector pathway.

Authors:  G A van Seventer; H J Salmen; S F Law; G M O'Neill; M M Mullen; A M Franz; S B Kanner; E A Golemis; J M van Seventer
Journal:  Eur J Immunol       Date:  2001-05       Impact factor: 5.532

6.  The docking protein HEF1 is an apoptotic mediator at focal adhesion sites.

Authors:  S F Law; G M O'Neill; S J Fashena; M B Einarson; E A Golemis
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

7.  Structure and function of Cas-L, a 105-kD Crk-associated substrate-related protein that is involved in beta 1 integrin-mediated signaling in lymphocytes.

Authors:  M Minegishi; K Tachibana; T Sato; S Iwata; Y Nojima; C Morimoto
Journal:  J Exp Med       Date:  1996-10-01       Impact factor: 14.307

8.  Reversal of the malignant phenotype of gastric cancer cells by inhibition of RhoA expression and activity.

Authors:  Na Liu; Feng Bi; Yanglin Pan; Lijun Sun; Yan Xue; Yongquan Shi; Xuebiao Yao; Yi Zheng; Daiming Fan
Journal:  Clin Cancer Res       Date:  2004-09-15       Impact factor: 12.531

9.  Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal tumor cells.

Authors:  Le Ba Thao; Hoang Anh Vu; Kazuki Yasuda; Shigeki Taniguchi; Fumiharu Yagasaki; Takahiro Taguchi; Toshiki Watanabe; Yuko Sato
Journal:  Cancer Biol Ther       Date:  2009-04       Impact factor: 4.742

10.  Dissection of HEF1-dependent functions in motility and transcriptional regulation.

Authors:  Sarah J Fashena; Margret B Einarson; Geraldine M O'Neill; Christos Patriotis; Erica A Golemis
Journal:  J Cell Sci       Date:  2002-01-01       Impact factor: 5.285

View more
  14 in total

1.  miR-145 functions as tumor suppressor and targets two oncogenes, ANGPT2 and NEDD9, in renal cell carcinoma.

Authors:  Ruijing Lu; Ziliang Ji; Xiaoqing Li; Qingna Zhai; Chunjuan Zhao; Zhimao Jiang; Shiqiang Zhang; Liping Nie; Zhendong Yu
Journal:  J Cancer Res Clin Oncol       Date:  2014-01-03       Impact factor: 4.553

2.  Overexpression of Nedd9 is a prognostic marker of human gastric cancer.

Authors:  Qi Zhang; Huiju Wang; Yingyu Ma; Jun Zhang; Xujun He; Jie Ma; Zhong-Sheng Zhao
Journal:  Med Oncol       Date:  2014-06-07       Impact factor: 3.064

3.  Expression of NEDD9 in pancreatic ductal adenocarcinoma and its clinical significance.

Authors:  Yu-Zheng Xue; Ying-Yue Sheng; Zong-Liang Liu; Zhe-Qiang Wei; Hai-Yan Cao; Yan-Min Wu; Yu-Feng Lu; Li-Hua Yu; Jian-Ping Li; Zhao-Shen Li
Journal:  Tumour Biol       Date:  2012-12-18

4.  High expression of NEDD9 predicts adverse outcomes of colorectal cancer patients.

Authors:  Peng Li; Houmin Zhou; Xinhong Zhu; Guiliang Ma; Chao Liu; Bin Lin; Weizheng Mao
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

5.  Elevated expression of NEDD9 is associated with metastatic activity in gastric cancer.

Authors:  Si-Sen Zhang; Li-Hua Wu; Qing Liu; Kui-Sheng Chen; Xie-Fu Zhang
Journal:  Onco Targets Ther       Date:  2015-03-10       Impact factor: 4.147

6.  Autoantibody Profiling of Glioma Serum Samples to Identify Biomarkers Using Human Proteome Arrays.

Authors:  Parvez Syed; Shabarni Gupta; Saket Choudhary; Narendra Goud Pandala; Apurva Atak; Annie Richharia; Manubhai K P; Heng Zhu; Sridhar Epari; Santosh B Noronha; Aliasgar Moiyadi; Sanjeeva Srivastava
Journal:  Sci Rep       Date:  2015-09-15       Impact factor: 4.379

7.  MicroRNA-145 suppresses cell proliferation, invasion and migration in pancreatic cancer cells by targeting NEDD9.

Authors:  Tong Han; Xiao-Ping Yi; Bo Liu; Mu-Jing Ke; Yi-Xiong Li
Journal:  Mol Med Rep       Date:  2015-02-03       Impact factor: 2.952

8.  FH535 inhibited migration and growth of breast cancer cells.

Authors:  Joji Iida; Jesse Dorchak; John R Lehman; Rebecca Clancy; Chunqing Luo; Yaqin Chen; Stella Somiari; Rachel E Ellsworth; Hai Hu; Richard J Mural; Craig D Shriver
Journal:  PLoS One       Date:  2012-09-11       Impact factor: 3.240

9.  NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma.

Authors:  Maria Carmela Speranza; Véronique Frattini; Federica Pisati; Dimos Kapetis; Paola Porrati; Marica Eoli; Serena Pellegatta; Gaetano Finocchiaro
Journal:  Oncotarget       Date:  2012-07

10.  High expression of HEF1 is associated with poor prognosis in urinary bladder carcinoma.

Authors:  Qi Zhang; Hui-Ju Wang; Da-Hong Zhang; Guo-Qing Ru; Xu-Jun He; Ying-Yu Ma
Journal:  Onco Targets Ther       Date:  2014-07-21       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.